Addex Therapeutics Advances GABAB PAM Chronic Cough Candidate, Dipraglurant for Post-Stroke Recovery

• Addex Therapeutics reported Q3 2025 financial results • Focused on developing small molecule allosteric modulators for neurological disorders • GABAB positive allosteric modulator candidate in chronic cough preclinical development • Advancing dipraglurant for clinical studies in post-stroke recovery • CEO Tim Dyer cited progress in chronic cough and post-stroke recovery programs • Company continues to advance GABAB PAM candidate and dipraglurant in preclinical development • Preparation underway for clinical studies in post-stroke recovery • Addex Therapeutics is a clinical-stage biopharmaceutical company • Headquartered in Geneva, Switzerland • Listed on SIX and Nasdaq under ticker ADXN